Safety of Sugammadex for the Reversal of Neuromuscular Blockade in American Society of Anesthesiologists (ASA) Class 3 or 4 Participants (MK-8616-145)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 344 participants.
Also called NCT03346057
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 344 participants
- Sponsor
- Registry
-
NCT03346057 -
2017-000187-15
-
- Other papers using this trial's data
- A randomized trial evaluating the safety profile of sugammadex in high surgical risk ASA physical class 3 or 4 participants
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Austria, Denmark, Germany
- Registry status
- Completed
Technical summary
Registry record NCT03346057. Randomized; triple masking; primary purpose treatment. Start 2017-12-20 (actual); primary completion 2019-09-04 (actual). Results posted on 2020-10-08.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety of Sugammadex for the Reversal of Neuromuscular Blockade in American Society of Anesthesiologists (ASA) Class 3 or 4 Participants (MK-8616-145)
- Condition
- Reversal of Neuromuscular Blockade
- Intervention (Drug)
- Sugammadex 2 mg/kg
- Intervention (Drug)
- Sugammadex 4 mg/kg
- Intervention (Drug)
- Sugammadex 16 mg/kg
- Intervention (Drug)
- Neostigmine + Glycopyrrolate
- Intervention (Drug)
- Rocuronium
- Intervention (Drug)
- Vecuronium
- Lead sponsor
- Merck Sharp & Dohme LLC
Record details
- Record id
cardio:ct-nct03346057- Content hash
deb02427309d6f7dd20111fecb5140512aff23e44e8b486a8ae896d02292ec34